(Q33348174)

26 July 2017

Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas (English)

1 reference

26 July 2017

Shreyaskumar R Patel

1

1 reference

26 July 2017

Jennifer Beach

2

1 reference

26 July 2017

Nicholas Papadopoulos

3

1 reference

26 July 2017

M Andrew Burgess

4

1 reference

26 July 2017

Jonathan Trent

5

1 reference

26 July 2017

Jan Jenkins

6

1 reference

26 July 2017

Robert S Benjamin

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

26 July 2017

1 reference

26 July 2017

97

1 reference

26 July 2017

11

1 reference

26 July 2017

2848-2852

1 reference

26 July 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11385

7 January 2021

New agents in the treatment of soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11385

7 January 2021

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11385

7 January 2021

Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11385

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11385

7 January 2021

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11385

7 January 2021

Identifiers

DOI

10.1002/CNCR.11385

1 reference

26 July 2017

1 reference